Asston Pharmaceuticals has announced its unaudited financial results for the half-year ended September 30, 2026. The company reported a net profit of ₹327.37 crore. This disclosure also includes the company’s statement of assets and liabilities and cash flow statement for the same period. The financial results were approved by the Board of Directors on November 12, 2026.
Asston Pharmaceuticals Releases Half-Year Financial Results
Asston Pharmaceuticals Limited has disclosed its unaudited financial results for the period ending September 30, 2026. The company announced a net profit of ₹327.37 crore for the half-year. The Board of Directors reviewed and approved these financial statements, along with a limited review report, on November 12, 2026.
Financial Highlights
The reported unadjusted financial results include a total income from operations of ₹1,681.32 lakhs for the six months ended September 30, 2026, compared to ₹1,468.14 lakhs in the previous period. Expenses for the same period amounted to ₹1,243.98 lakhs. The company’s net profit before tax stood at ₹437.33 lakhs.
The statement of assets and liabilities as of September 30, 2026, shows total assets of ₹8,314.53 lakhs and total equity and liabilities of ₹8,314.53 lakhs. Key figures for shareholders’ funds include equity share capital of ₹1,092.28 lakhs and reserves and surplus of ₹5,892.89 lakhs. Non-current liabilities were ₹330.90 lakhs, while current liabilities were ₹998.47 lakhs.
Cash Flow Statement Insights
The unaudited cash flow statement for the half-year ended September 30, 2026, indicates a net cash used in operating activities of ₹656.69 lakhs. Investing activities resulted in a net cash outflow of ₹620.93 lakhs, primarily due to the purchase of property, plant, and equipment, and investments in fixed deposits. Financing activities generated a net cash inflow of ₹2,747.16 lakhs, largely from the issue of equity share capital and premium.
The company’s cash and cash equivalents at the end of the period stood at ₹1,598.63 lakhs.
Source: BSE
